The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
September 7th 2024
This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.
Clinical Trial Reports: September 2007
July 8th 2010The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer, and more
Clinical Trial Reports: July/August 2007
July 7th 2010Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more
Clinical Trial Reports: October 2007
June 30th 2010The Clinical Trials reported include: PHASE III: 1) Is Combination or Sequential Treatment for Metastatic Colorectal Cancer More Effective? 2) Cervical Cancer Vaccines Do Not Work Like Investigational Cancer Vaccines, Study Confirms 3) Docetaxel to Improve Clinical and Quality of Life Improvement in the Treatment of Advanced Gastric or Gastroesophageal Cancer, and more
Clinical Trial Reports: November 2007
June 29th 2010The Clinical Trials Reported in this issue include: PHASE III: 1) Trastuzumab and Anastrozole Extend Breast Cancer Survival in Patients Who Received Anastrozole Alone Earlier PHASE II: 1) Motexafin for Non%u2013Small Cell Lung Cancer 2) Oral Satraplatin Monotherapy for the Treatment of Metastatic Breast Cancer Shows Little Response, and more
Opportunities and Challenges: A Time to Reflect at the End of a Busy Year
December 29th 2008It is the final month of what has been economically a very tough year. Oncology centers and practices continue to face declining reimbursements on all service lines, and most have had either flat or lower revenues.